Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Martin Burke, MD, PhD
Founder of cystetic Medicines
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Canberra Hospital
Canberra, Australian Capital Territory, Australia
Recruiting - Westmead Hospital
Westmead, New South Wales, Australia
Recruiting - the Prince Charles Hospital
Brisbane, Queensland, Australia
Recruiting - Monash Medical Centre
Clayton, Victoria, Australia
Recruiting
- New Zealand Clinical Research
Christchurch, New Zealand
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Mar 2023
- Primary completion
- 31 Dec 2025
- Completion
- 31 Dec 2025
- Last update posted
- 12 Feb 2025
- Registered enrollment
- 108
- Registry id
- NCT05802264
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.